Trial Profile

Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy Study

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 29 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mannitol (Primary)
Indications Cystic fibrosis
Focus Registrational; Therapeutic Use
Sponsors Pharmaxis; Syntara Limited

Most Recent Events

04 Dec 2023 According to a Syntara Limited media release, Pharmaxis has changed its name to Syntara Limited
28 Jul 2017 This trial was discontinued in United Kingdom.
26 Oct 2010 According to a Pharmaxis media release, pooled data from its 2 large scale 6-month phase III trials of mannitol in patients with cystic fibrosis have been presented at the North American Cystic Fibrosis Conference.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com